Epitomics spins off mAb company Apexigen

Burlingame, CA-based Epitomics has spun off a new biotech called Apexigen, which will focus on developing humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics' rabbit monoclonal antibody technology and the mutational lineage guided humanization technology. The company will use the technologies to develop therapies for both humans and animals.

Xiaodong Yang has been appointed as president and CEO of the new company. An agreement with Epitomics gives Apexigen full access to the company's antibody generation, screening infrastructure.

"We believe that an independent company with experience, expertise and focused pharmaceutical product development offers the best opportunity to see technology developed at Epitomics have a direct therapeutic impact on peoples' lives," says Guo-Liang Yu, president & CEO of Epitomics. "Epitomics will continue to focus on its core business and assist Apexigen as it develops therapeutics to treat serious diseases."

- check out the Epitomics release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.